Cabozantinib and atezolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a combination of two drugs, cabozantinib and atezolizumab, for people with advanced lung cancer that has low PD-L1 levels. The goal is to see if this combination can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic non-small cell lung cancer that has low levels of a protein called PD-L1 (less than 1%).
- If you have specific genetic changes in the tumor, you must have already tried and not responded to targeted therapy for those changes.
- You have not received any prior cancer therapy, or only targeted therapy if you had a genetic change and it stopped working.
- You are able to perform daily activities with some help (ECOG 0-1).
- You have a tumor sample available for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial studies how well cabozantinib works in advanced lung cancer when the tumor has certain gene changes (like RET, ROS1, NTRK, MET, or AXL). It may help slow tumor growth after standard treatments, depending on your tumor test results.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.